Occult hepatitis B and HIV infection

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Occult hepatitis B infection (OBI) is defined by detectable hepatitis B virus DNA (HBV-DNA) without hepatitis B surface antigen (HBsAg).
• OBI involves replication-competent HBV produced in the liver, with fluctuating low-level HBV-DNA in the blood.
• OBI represents an intermediate state between chronic and resolved HBV infection.

Purpose of the Study:

• To investigate the prevalence and implications of OBI in the context of HIV infection.
• To understand the impact of antiretroviral therapy on OBI in individuals with HIV.
• To assess the potential for OBI resurgence with evolving HIV treatment strategies.

Main Methods:

• Review of existing literature and clinical data on OBI in HIV-positive individuals.
• Analysis of the role of HBV vaccination and recall campaigns in the HIV population.
• Evaluation of the impact of specific antiretroviral agents (tenofovir, lamivudine, emtricitabine) on HBV replication and OBI.

Main Results:

• OBI was previously considered more frequent in AIDS patients but is now negligible in the HIV population.
• Widespread HBV immunization and the use of anti-HBV active antiretroviral regimens have significantly reduced OBI prevalence.
• HBV reactivation and transmission associated with HIV have become rare due to effective antiviral suppression.

Conclusions:

• Current antiretroviral therapies have dramatically decreased OBI-related complications in HIV patients.
• The increasing popularity of tenofovir-sparing antiretroviral regimens may pose a risk for OBI resurgence in the HIV setting.
• Continued vigilance and research are necessary to monitor and manage OBI in evolving HIV treatment landscapes.